Print full article

Companion Animal Health targets mast cell tumors with nanomedicine

Companion Animal Health and Nanospectra Biosciences partner to deliver combined laser and nanoshell therapy to destroy tumors

Suggested Veterinary Products

Hand of the veterinarian shows metastases on the dog’s body.

Companion Animal Health (CAH) in Newark, Del., has secured an exclusive partnership with Nanospectra Biosciences Inc., a medical device company focused on the use of nanomedicine in selective thermal ablation of solid tumors.

In 2017, CAH initiated clinical trials in the treatment of canine mast cell tumors using a combined laser and nanoshell therapy procedure that has the ability to destroy solid tumors without damaging adjacent healthy tissue.

“Initial results are very encouraging and we anticipate publishing trial outcomes in the near future,” said Brian Pryor, PhD, CEO, LiteCure LLC. “We believe this approach will deliver superior efficacy compared to commonly used cancer treatments and will extend pets’ quality of life and longevity without harmful side effects.”

Visit companionanimalhealth.com for more information.




Leave a Comment


Your email address will not be published. Required fields are marked *


Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.